top of page

TAGRISSO in the Treatment of Resectable NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Mutations

This 60-minute program includes a presentation and a question-and-answer session about the adjuvant treatment of resectable EGFR mutation-positive non-small cell lung cancer (NSCLC).


• TAGRISSO is indicated as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test


• There are no contraindications for TAGRISSO

• Interstitial lung disease (ILD)/pneumonitis occurred in 3.7% of the 1479 TAGRISSO-treated patients; 0.3% of cases were fatal. Withhold TAGRISSO and promptly investigate for ILD in patients who present with worsening of respiratory symptoms which may be indicative of ILD (eg, dyspnea, cough and fever). Permanently discontinue TAGRISSO if ILD is confirmed SPEAKERS

The virtual program will start promptly at 6:30 pm.

Please RSVP by February 1, 2021.

If you have questions about this program, you may contact your AstraZeneca representative Tara Clark at

ADAURA Webcast PDF Invite_Feb2_NY_Final
Download • 13.20MB

25 views0 comments


bottom of page